Boardroom Alpha
10-K primary document
HAE · Annual Report (Form 10-K) · Filed May 20, 2026

Haemonetics Corp10-K exhibit

fy2026ex211.htm
Document

Exhibit 21.1 - Subsidiaries of the Company
Subsidiary of Haemonetics CorporationJurisdiction of Incorporation or Organization
5D Information Management, Inc.Delaware
Advanced Cooling Therapy, LLCDelaware
Arryx, Inc.Nevada
Cardiva Medical, Inc.Delaware
Enicor GmbHGermany
Global Med Technologies, Inc.Colorado
Haemonetics (Hong Kong) LimitedHong Kong
Haemonetics Asia IncorporatedDelaware
Haemonetics Asia UK Ltd.United Kingdom
Haemonetics Australia PTY Ltd.Victoria
Haemonetics Canada Ltd.British Columbia
Haemonetics CZ, spol. s.r.o.Czech Republic
Haemonetics France S.a.r.lFrance
Haemonetics GmbHGermany
Haemonetics Handelsgesellschaft m.b.H.Austria
Haemonetics Healthcare India Private LimitedIndia
Haemonetics Interventional Technologies LimitedIreland
Haemonetics Italia s.r.l.Italy
Haemonetics Japan GKJapan
Haemonetics Korea, Inc.Seoul, Korea
Haemonetics LimitedUnited Kingdom
Haemonetics Malaysia Sdn. Bhd.Malaysia
Haemonetics Manufacturing, Inc.Delaware
Haemonetics (Shanghai) Management Co. Ltd.Shanghai,China
Haemonetics Mexico Manufacturing, S.de R.L. de C.V.Mexico
Haemonetics New Zealand LimitedNew Zealand
Haemonetics S.A.Switzerland
Haemonetics Singapore Pte. Ltd.Singapore
Haemoscope CorporationMassachusetts
OpSens B.V.Netherlands
OpSens Inc.Quebec
OpSens Medical, Inc.Delaware
OpSens Solutions Inc.Alberta
Vivasure Medical LimitedIreland
Vivasure Medical UK Ltd.United Kingdom
Vivasure Medical US, Inc.Delaware


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer